NASDAQ:NAUT Nautilus Biotechnology (NAUT) Stock Price, News & Analysis $2.61 +0.01 (+0.38%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Nautilus Biotechnology Stock (NASDAQ:NAUT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nautilus Biotechnology alerts:Sign Up Key Stats Today's Range$2.60▼$2.7250-Day Range$2.48▼$3.0852-Week Range$2.19▼$3.45Volume39,043 shsAverage Volume74,448 shsMarket Capitalization$327.71 millionP/E RatioN/ADividend YieldN/APrice Target$4.50Consensus RatingModerate Buy Company OverviewNautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Nautilus Biotechnology Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks39th Percentile Overall ScoreNAUT MarketRank™: Nautilus Biotechnology scored higher than 39% of companies evaluated by MarketBeat, and ranked 733rd out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingNautilus Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNautilus Biotechnology has received no research coverage in the past 90 days.Read more about Nautilus Biotechnology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nautilus Biotechnology are expected to decrease in the coming year, from ($0.65) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nautilus Biotechnology is -4.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nautilus Biotechnology is -4.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNautilus Biotechnology has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nautilus Biotechnology's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.61% of the float of Nautilus Biotechnology has been sold short.Short Interest Ratio / Days to CoverNautilus Biotechnology has a short interest ratio ("days to cover") of 16.7, which indicates bearish sentiment.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNautilus Biotechnology does not currently pay a dividend.Dividend GrowthNautilus Biotechnology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.61% of the float of Nautilus Biotechnology has been sold short.Short Interest Ratio / Days to CoverNautilus Biotechnology has a short interest ratio ("days to cover") of 16.7, which indicates bearish sentiment.Change versus previous month News and Social Media1.8 / 5News Sentiment0.23 News SentimentNautilus Biotechnology has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Nautilus Biotechnology this week, compared to 1 article on an average week. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nautilus Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $234,729.00 in company stock.Percentage Held by Insiders40.50% of the stock of Nautilus Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions50.71% of the stock of Nautilus Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nautilus Biotechnology's insider trading history. Receive NAUT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address NAUT Stock News HeadlinesNautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2024 Earnings Call TranscriptOctober 31 at 5:32 PM | msn.comNautilus Biotechnology Faces ESG Challenges Amid Regulatory Pressure and Investor ScrutinyOctober 31 at 5:32 PM | markets.businessinsider.comCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!November 2, 2024 | Crypto 101 Media (Ad)Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research's Distinguished Investigator AwardOctober 31 at 8:00 AM | globenewswire.comNautilus Biotechnology Inc (NAUT) Q3 2024 Earnings Call Highlights: Strategic Advances and ...October 30 at 10:51 AM | finance.yahoo.comNautilus Biotechnology Reports Q3 2024 Financial ResultsOctober 30 at 10:51 AM | msn.comNautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare ConferenceOctober 30 at 8:00 AM | globenewswire.comNautilus Biotechnology Reports Third Quarter 2024 Financial ResultsOctober 30 at 5:49 AM | markets.businessinsider.comSee More Headlines NAUT Stock Analysis - Frequently Asked Questions How have NAUT shares performed this year? Nautilus Biotechnology's stock was trading at $2.99 at the beginning of 2024. Since then, NAUT stock has decreased by 12.7% and is now trading at $2.61. View the best growth stocks for 2024 here. How were Nautilus Biotechnology's earnings last quarter? Nautilus Biotechnology, Inc. (NASDAQ:NAUT) posted its earnings results on Tuesday, October, 29th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.04. Who are Nautilus Biotechnology's major shareholders? Top institutional investors of Nautilus Biotechnology include China Universal Asset Management Co. Ltd. (0.02%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Sujal M Patel, Subramanian Sankar, Anna Mowry, Matthew B Murphy, Gwen E Weld, Perceptive Advisors Llc, Mary E Godwin, Matthew L Posard and Matthew S Mcilwain. View institutional ownership trends. How do I buy shares of Nautilus Biotechnology? Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Nautilus Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nautilus Biotechnology investors own include JPMorgan Chase & Co. (JPM), Netflix (NFLX), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Home Depot (HD) and Visa (V). Company Calendar Last Earnings10/29/2024Today11/02/2024Fiscal Year End12/31/2024Next Earnings (Estimated)2/26/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:NAUT CUSIPN/A CIK1808805 Webwww.nautilus.bio Phone206-333-2001FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Stock Price Target$4.50 High Stock Price Target$6.00 Low Stock Price Target$3.00 Potential Upside/Downside+72.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.85% Return on Assets-24.93% Debt Debt-to-Equity RatioN/A Current Ratio16.65 Quick Ratio19.69 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.78 per share Price / Book1.47Miscellaneous Outstanding Shares125,560,000Free Float74,620,000Market Cap$327.71 million OptionableOptionable Beta1.22 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:NAUT) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nautilus Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nautilus Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.